Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma

Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences.

Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma (NPC) is the first to receive breakthrough designation in China. NPC is one among the most common malignant tumors seen in the people of China. Compared with the world average, the number of people affected with NCP is more in China.

Earlier patients with nasopharyngeal carcinoma would have a good therapeutic effect with 90% can be cured or be tumor-free for a long time lacking specific clinical symptoms.

US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma (NPC) is a malignant tumor which generally occurs in the mucosal epithelium of the nasopharynx, mainly in the parietal and lateral walls of the nasopharynx, particularly in the pharyngeal recess.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024